New hope for hard-to-treat colorectal cancer: experimental combo enters human trials
NCT ID NCT07391566
First seen Feb 06, 2026 · Last updated May 25, 2026 · Updated 14 times
Summary
This study tests a new drug, LPM6690176, combined with standard chemotherapy and bevacizumab for people with a specific genetic form of metastatic colorectal cancer (RAS mutation). The trial has two parts: first, finding the safest dose in about 99 adults who have already tried one treatment; second, comparing the new combo against standard therapy in patients who have not yet been treated for advanced disease. The goal is to see if the new combination can shrink tumors better and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.